New TYSABRI(R) Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis



    Study Shows Increased Proportion of Patients Achieve Disease-Free Status
with TYSABRI

    Separate Study Demonstrates Plasma Exchange May Be an Effective Tool to
Accelerate TYSABRI Removal

    PRAGUE, CZECH REPUBLIC, October 11 /CNW/ - Biogen Idec (NASDAQ:   BIIB) and
Elan Corporation, plc (NYSE:   ELN) announced that TYSABRI(R) (natalizumab)
treatment significantly increases the proportion of disease-free patients with
multiple sclerosis (MS) according to a post hoc analysis of the Phase III
AFFIRM study to be presented on Saturday, October 13, 2007 at the 23rd
Congress of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) in Prague, Czech Republic. Also to be presented on
Saturday will be findings from the PLEX study which suggest that plasma
exchange may be an effective means of accelerating the removal of TYSABRI from
the circulation.

    Post Hoc Analysis of Phase III AFFIRM Study

    The proportion of disease-free patients in the AFFIRM study was
determined based upon clinical and MRI criteria. The proportion of
disease-free patients over two years was significantly higher in the
TYSABRI-treated group compared with the placebo group regardless of how
disease free was defined.

    Clinically, disease free was defined as no relapses and no progression of
disability (as defined by (greater than) or =1.0-point increase in Expanded
Disability Status Scale (EDSS) score from a baseline score of (greater than)
or =1.0, or a (greater than) or =1.5-point increase from a baseline score of
0.0, sustained for 12 weeks) over two years. MRI disease free was defined as
no gadolinium-enhancing lesions and no new or enlarging T2-hyperintense
lesions.

    Using clinical and MRI disease-free criteria combined, the most stringent
definition of disease free, 36.7% of TYSABRI-treated patients had no relapses,
disability progression or MRI activity compared with 7.2% of placebo patients
(p(less than)0.0001). In the clinical analysis, 64.3% of TYSABRI-treated
patients vs. 38.9% placebo-treated patients(p(less than)0.0001) were disease
free or without relapses and disability progression. Using MRI measures, 57.7%
of TYSABRI-treated patients vs. 14.2% placebo-treated patients (p(less
than)0.0001); were disease free, or without gadolinium-enhancing lesions and
new or enlarging T2-hyperintense lesions.

    "These data demonstrate the dramatic effect TYSABRI can have on critical
measures of multiple sclerosis. In addition to the impact on individual
clinical and MRI outcomes, it is striking that more than one-third of patients
were free of relapses, disability progression and MRI activity after two years
of treatment. This suggests that TYSABRI may offer patients freedom from many
of their MS symptoms," said Eva Havrdova, MD, PhD, Director of the Center for
Demyelinating Diseases at the First School of Medicine, General University
Hospital, Charles University, Prague, Czech Republic.

    PLEX Plasma Exchange Study

    Results from the PLEX study also to be presented suggest that plasma
exchange may be an effective means of accelerating the removal of TYSABRI from
blood serum. Plasma exchange is one of several research efforts the companies
have underway to learn more about potential interventions or treatments for
progressive multifocal leukoencephalopathy (PML), a rare side effect of
TYSABRI.

    "These data from the PLEX study are encouraging as they show the removal
of TYSABRI is faster following plasma exchange. Time will tell whether plasma
exchange develops as an effective treatment approach for PML," said Bhupendra
O. Khatri, MD, Medical Director of the Regional MS Center, Aurora St. Luke's
Medical Center, Milwaukee, WI.

    PLEX is an open-label, single-arm, multicenter exploratory study
involving 12 patients with relapsing-remitting MS designed to explore whether
plasma exchange could significantly reduce the concentration of TYSABRI in
blood serum and alpha 4-integrin receptor saturation. Based on the PLEX
findings, plasma exchange was effective at accelerating the normal decline of
serum TYSABRI concentrations.

    Plasma exchange was generally well tolerated with no increase in MS
disease activity following plasma exchange. There were no study
discontinuations due to adverse events and all patients returned to TYSABRI
treatment without complications. Further investigations are needed to
determine whether plasma exchange holds promise as an intervention in the
setting of PML.

    About TYSABRI

    TYSABRI is a treatment approved for relapsing forms of MS in the United
States and relapsing-remitting MS in the European Union. According to data
that have been published in the New England Journal of Medicine, after two
years, TYSABRI treatment led to a 68% relative reduction (p(less than)0.001)
in the annualized relapse rate compared to placebo and reduced the relative
risk of disability progression by 42-54% (p(less than)0.001).

    TYSABRI increases the risk of progressive multifocal leukoencephalopathy
(PML), an opportunistic viral infection of the brain that usually leads to
death or severe disability. Other serious adverse events that have occurred in
TYSABRI-treated patients included hypersensitivity reactions (e.g.,
anaphylaxis) and infections. Serious opportunistic and other atypical
infections have been observed in TYSABRI-treated patients, some of whom were
receiving concurrent immunosuppressants. Herpes infections were slightly more
common in patients treated with TYSABRI. In MS trials, the incidence and rate
of other serious and common adverse events, including the overall incidence
and rate of infections, were balanced between treatment groups. Common adverse
events reported in TYSABRI-treated patients include headache, fatigue,
infusion reactions, urinary tract infections, joint and limb pain, and rash.

    In addition to the United States and European Union, TYSABRI is also
approved in Switzerland, Canada, Australia, New Zealand and Israel. TYSABRI
was discovered by Elan and is co-developed with Biogen Idec.

    For more information about TYSABRI please visit www.tysabri.com,
www.biogenidec.com or www.elan.com, or call 1-800-456-2255.

    About Biogen Idec

    Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the
discovery, development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from Biogen Idec's
significant products that address diseases such as lymphoma, multiple
sclerosis, and rheumatoid arthritis. For product labeling, press releases and
additional information about the company, please visit www.biogenidec.com.

    About Elan

    Elan Corporation, plc is a neuroscience-based biotechnology company
committed to making a difference in the lives of patients and their families
by dedicating itself to bringing innovations in science to fill significant
unmet medical needs that continue to exist around the world. Elan shares trade
on the New York, London and Dublin Stock Exchanges. For additional information
about the company, please visit www.elan.com.

    Safe Harbor/Forward-Looking Statements

    This press release contains forward-looking statements regarding TYSABRI
and the PLEX study. These statements are based on the companies' current
beliefs and expectations. The commercial potential of TYSABRI is subject to a
number of risks and uncertainties. Factors which could cause actual results to
differ materially from the companies' current expectations include the risk
that we may be unable to adequately address concerns or questions raised by
FDA or other regulatory authorities, that concerns may arise from additional
data, that the incidence and/or risk of PML or other opportunistic infections
in patients treated with TYSABRI may be higher than observed in clinical
trials, or that the companies may encounter other unexpected hurdles. Drug
development and commercialization involves a high degree of risk.

    For more detailed information on the risks and uncertainties associated
with the companies' drug development and other activities, see the periodic
and current reports that Biogen Idec and Elan have filed with the Securities
and Exchange Commission. The companies assume no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.




For further information:

For further information: Media Contacts: Biogen Idec Amy Reilly,
617-914-6524 or Elan Jonathan Birt, 212-850-5664 or Elizabeth Headon, 353 1
498 0300 or Investor Contacts: Biogen Idec Eric Hoffman, 617-679-2812 or Elan
Chris Burns, 353 1 709 4444 800 252 3526

Organization Profile

BIOGEN IDEC

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890